This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
SSE (SSE) – cuts dividend outlook; FY 17/18 adj. operating profit -2.4%, adj. pre-tax profit -6%, adj. net debt +8.7%, final and FY div +3.7%; expects 2018/19 div +3% (RPI), 19/20 -18% after nPower transaction and Tariff Cap, then 20-23 increase at RPI. Closing price: 1415.50p (Source: DowJones)
Spectris (SXS) – CEO of 12 years to leave within 12 months; Like-For-Like sales +6% in first four months of 2018; 5% FX drag on sales means net 2% growth (incl. acquisitions), in-line with guidance but order book visibility limited; net debt higher after acquisition, buyback and CAPEX. Closing price: 2791p (Source: DowJones)
AstraZeneca (AZN) – Imfinzi met second of two primary endpoints in Phase III Pacific trial, significantly improving overall survival rate in stage III non-small cell lung cancer (NSCLC). Closing price: 5428p (Source: DowJones)
Pennon (PNN) – FY 2018 pre-tax profit +25% beats consensus, revenues in-line; dividend +7.3%; outlook for water and water is positive. Closing price: 730p (Source: DowJones)
Centamin (CEY) – cuts production guidance for Sukari Gold mine due to persistently low grades, expects weaker Q2 but strong Q3 and Q4. Closing price: 159.35p (Source: DowJones)
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research